Atrial Flutter
📧 Sign up to get email alerts when something new happens for Atrial Flutter.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-03-16Clinical Trial Update: Multipolar Mapping and Atrial Arrhythmias [NA]
A completed clinical trial investigating multipolar mapping for atrial fibrillation and atrial flutter, with results posted in 2016.
-
FDA approval · 2016-03-08FDA Approved: TIKOSYN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for TIKOSYN (dofetilide) from Pfizer Laboratories Div Pfizer Inc.
-
CLINICAL_TRIALS trial_result · 2016-03-03Clinical Trial Update: Evaluation of Thermocool SF Catheter on the Common Cavo-tricuspid Isthmus Dependent Atrial Flutter Ablation [Phase 4]
Phase 4 clinical trial update on using the ThermoCool SF Catheter for cavotricuspid isthmus–dependent atrial flutter ablation; current statu…
-
FDA approval · 2016-02-12FDA Approved: MULTAQ — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for MULTAQ (dronedarone) submitted by Sanofi-Aventis U.S. LLC. The document describes the agency…
-
FDA approval · 2016-01-10FDA Approved: DIGOXIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Digoxin from Hikma Pharmaceuticals USA Inc., indicating a supplemental approval (AP) for the pro…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2016-01-05Clinical Trial Update: PREdicting Atrial Fibrillation or Flutter
This document provides a clinical trial update on predicting atrial fibrillation or atrial flutter.
-
CLINICAL_TRIALS trial_result · 2015-12-22Clinical Trial Update: Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm [Phase 2]
A Phase 2 study of vanoxerine for converting symptomatic atrial fibrillation or atrial flutter to normal sinus rhythm has completed with res…
-
FDA approval · 2015-11-25FDA Approved: TIKOSYN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Tikosyn (dofetilide) from Pfizer Laboratories Div Pfizer Inc. The action represents a supplement…
-
FDA approval · 2015-11-20FDA Approved: DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved a supplemental application for diltiazem hydrochloride extended-release from Oceanside Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2015-11-17Clinical Trial Update: RF Lesion Monitoring With 8mm IntellaTip MiFi XP
This clinical trial update notes the completion of a study evaluating RF lesion monitoring with the 8mm IntellaTip MiFi XP catheter for atri…
-
FDA approval · 2015-10-26FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for verapamil hydrochloride (Actavis Pharma, Inc.), a generic product.
-
FDA approval · 2015-10-14FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Verapamil Hydrochloride (generic) from Chartwell RX, LLC.
-
FDA approval · 2015-10-05FDA Approved: AMIODARONE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for amiodarone hydrochloride submitted by Sun Pharmaceutical Industries, Inc.
-
FDA label_change · 2015-09-25FDA Approved: SOTALOL HYDROCHLORIDE — Supplemental Application (ALTATHERA Pharmaceuticals, LLC)
The FDA approved a supplemental application for Sotalol Hydrochloride submitted by ALTATHERA Pharmaceuticals, LLC, to modify the product lab…
-
CLINICAL_TRIALS trial_result · 2015-09-23Clinical Trial Update: Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter [Phase 2]
Phase 2 clinical trial comparing adding botulinum toxin injections to radiofrequency ablation versus radiofrequency ablation alone in patien…
-
CLINICAL_TRIALS research · 2015-09-23Clinical Trial Update: Cryoablation in Patients With Atrial Flutter [Phase 2]
A Phase 2 clinical trial is evaluating cryoablation for atrial flutter, with the current trial status not disclosed.
-
FDA approval · 2015-08-27FDA Approved: PROPAFENONE HYDROCHLORIDE — Supplemental Application (Strides Pharma Science Limited)
The FDA approved Strides Pharma Science Limited's supplemental application for propafenone hydrochloride, enabling a generic version of this…
-
FDA approval · 2015-08-25FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
FDA approves Apotex Corp.'s supplemental application for diltiazem hydrochloride (generic) under an abbreviated new drug application (ANDA).
-
FDA approval · 2015-08-13FDA Approved: PACERONE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for PACERONE (amiodarone hydrochloride) from Upsher-Smith Laboratories.
-
FDA approval · 2015-08-13FDA Approved: PROPAFENONE HCL — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for Propafenone hydrochloride (Propafenone HCl) from Actavis Pharma, Inc.
-
CLINICAL_TRIALS research · 2015-08-13Clinical Trial Update: High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter
This completed study evaluates high-sensitivity troponin T levels after direct current cardioversion in patients with atrial fibrillation or…
-
FDA approval · 2015-07-28FDA Approved: LANOXIN — Supplemental Application (Advanz Pharma (US) Corp.)
FDA approves a supplemental application for LANOXIN (digoxin) from Advanz Pharma (US) Corp., under the supplemental NDA framework.
-
FDA label_change · 2015-07-28FDA Approved: LANOXIN — Supplemental Application (Covis Pharma US, Inc)
The FDA approved a supplemental application for Lanoxin (digoxin) submitted by Covis Pharma US, Inc.
-
CLINICAL_TRIALS trial_result · 2015-07-28Clinical Trial Update: Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter [Phase 3]
Phase 3 trial evaluating prevention of atrial fibrillation after atrial flutter ablation using Inhibition Conversion Enzyme (ICE) has been t…
-
FDA approval · 2015-07-08FDA Approved: TIKOSYN — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for Tikosyn (dofetilide) from Pfizer Laboratories Div Pfizer Inc.